Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 3/20 | 0.58 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12537108 | 1.00 | RARB (0.58) | RARBNR5A1CYP3A4CYP2D6SLC2A1 | |
| SCHEMBL18314262 | 1.00 | RARB (0.58) | RARBNR5A1CYP3A4CYP2D6SLC2A1 | |
| SCHEMBL17946790 | 1.00 | RARB (0.58) | RARBNR5A1CYP3A4CYP2D6SLC2A1 | |
| SCHEMBL12537090 | 0.98 | CYP3A4 (0.56) | RARBNR5A1CYP3A4CYP2D6SLC2A1 | |
| SCHEMBL16557180 | 0.98 | CYP3A4 (0.56) | RARBNR5A1CYP3A4CYP2D6SLC2A1 | |
| SCHEMBL12537096 | 0.95 | NR5A1 (0.61) | NR5A1SLC2A1LTA4HLMNATP53 | |
| SCHEMBL8123234 | 0.95 | NR5A1 (0.61) | NR5A1SLC2A1LTA4HLMNATP53 | |
| SCHEMBL21655109 | 0.95 | NR5A1 (0.61) | NR5A1SLC2A1LTA4HLMNATP53 | |
| SCHEMBL15000418 | 0.95 | NR5A1 (0.61) | NR5A1SLC2A1LTA4HLMNATP53 | |
| SCHEMBL15762476 | 0.95 | NR5A1 (0.61) | NR5A1SLC2A1LTA4HLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321251-A1 | LIPOSOME FORMULATION CONTAINING ANTIBACTERIAL AGENT | OSAKA UNIVERSITY (JP) | 2023-10-12 | — | — | US | disclosed |
| WO-2016201283-A1 | ANTIFUNGAL AGENTS | CIDARA THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| WO-2015035102-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-7902148-B2 | Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent | THERAVANCE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090221470-A1 | USE OF AN ECHINOCANDIN ANTIFUNGAL AGENT IN COMBINATION WITH A GLYCOPEPTIDE ANTIBACTERIAL AGENT | CUMBERLAND PHARMACEUTICALS INC. | 2009-09-03 | — | — | US | disclosed |
| US-7452861-B2 | Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent | THERAVANCE, INC. (US) | 2008-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321251-A1 | LIPOSOME FORMULATION CONTAINING ANTIBACTERIAL AGENT | LIPA, LIPG, LIPC | RARB 2288/4885NR5A1 3602/4885CYP3A4 2847/4885 |
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | FPR1, FPR3, FPR2 | RARB 2983/4885NR5A1 2683/4885CYP3A4 2774/4885 |
| US-20090221470-A1 | USE OF AN ECHINOCANDIN ANTIFUNGAL AGENT IN COMBINATION WITH A GLYCOPEPTIDE ANTIBACTERIAL AGENT | DPM1, ERG28, ENGASE | RARB 4821/4885NR5A1 4197/4885CYP3A4 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.